Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach

Area of Science:

• Immunology
• Allergy Research
• Pharmacology

Background:

• Allergic rhinoconjunctivitis (AR) is a prevalent IgE-mediated condition driven by type 2 immune responses.
• Allergic inflammation involves eosinophilic infiltration and mediator release, often managed with antihistamines and intranasal corticosteroids.
• Long-term medication use and variable efficacy necessitate exploring alternative and complementary strategies for AR.

Purpose of the Study:

• To introduce a novel nutraceutical compound designed for allergic rhinoconjunctivitis management.
• To explore the potential of complementary medicine, specifically nutraceuticals, in addressing AR treatment challenges.

Main Methods:

• Development of a new compound combining Vitamin D3, Perilla extract, and quercetin.
• Focus on nutraceuticals as a therapeutic option in clinical practice for allergic diseases.

Main Results:

• A novel compound has been formulated incorporating key ingredients with potential anti-inflammatory properties.
• The study highlights the growing interest in nutraceuticals as adjunct therapies for allergic conditions.

Conclusions:

• Nutraceuticals, such as the newly designed compound, represent promising complementary therapeutic options for allergic rhinoconjunctivitis.
• This approach addresses the need for alternative strategies when conventional AR medications are insufficient or require prolonged use.